Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart cafraglutide autoinjector in obesity or overweight
NCT07871409Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 3 trial of maridebart cafraglutide in obesity, sponsored by Amgen. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07871409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871409.